⌕
Scinai Immunotherapeutics · SCNI · Nasdaq
Tenet 21 · Weak
Compare
$1.55+323.14%At closeTenet 21 · Weak
$1.55+1.19 (+323.14%)
At close: Nov 19, 2026, 4:00 PM ET· Nasdaq · USD

Scinai Immunotherapeutics (SCNI) Earnings Forecast

What Wall Street expects this business to earn, and how much analysts disagree.

Sources Analyst estimates EstimatesConsensus as of How we compute thisNot investment advice

Are estimates going up or down lately?

We hold no eps window in 90 days for the near year yet. Every figure here compares one fiscal period at both ends.

No step line for this window yet. A line needs two nights of one fiscal period inside the window to join, and our record does not hold two.

EPS30 days90 daysshown aboveSince Jul 10
Dec '261 analyst◆ 0.0%$−8.50 to $−8.5086 of 90 days0.0% so far◆ 0.0%$−8.50 to $−8.50
Mar '271 analyst5 of 30 days0.0% so far5 of 90 days0.0% so far◆ 0.0%$−85.00 to $−85.00

Measured between two of our own nightly snapshots of one fiscal period, so a new fiscal year entering the view is never read as a revision. Never backfilled. A window still filling says how many days it holds; a blank one means our record is not that long yet.

We hold no forward multiple for Scinai Immunotherapeutics today, so there is nothing here to set against the growth the Street expects.

Is next quarter a high bar or an easy one?

Analysts expect Scinai Immunotherapeutics to lose $8.50 a share in the December quarter, the one estimate published. We hold no expected date for the next report.

Expected report
Not held
No expected date is published for this company's next report, so none is printed here.
Revenue expected · December quarter
$1,961.7K
1 analyst, 1,961.7 to 1,961.7 in $K

For the March quarter, analysts expect a loss of $85.00 a share.

Does Scinai Immunotherapeutics usually beat or miss?

We have not been able to check a quarter yet. Our record of estimates for Scinai Immunotherapeutics begins on Jul 10, 2026, and a quarter can be checked only when we hold an estimate for it from before the company reported.

We started recording estimates on Jul 10, 2026, so quarters that reported before that date cannot be checked.

Before our record
Mar '22
Mar '23
Our record, one quarter per report
Dec '26not reported yet
Mar '27
Jun '27
Sep '27
Dec '27
Mar '28
Jun '28
Sep '28
Dec '28
Mar '29
Jun '29
Sep '29
Checked so far
None yet
one more every report
Beat expectations
Nothing to count
scores begin at the next report
Share price reaction
Not held
there is no checked quarter to measure a reaction for
Typical gap vs estimate
Not yet
shown once 4 quarters are checked

Checked against the company's reported figure (GAAP) and the average estimate we recorded the night before its results release. Where analysts' number is on an adjusted basis, we leave the comparison out rather than force it. We started recording estimates for Scinai Immunotherapeutics on Jul 10, 2026, so earlier quarters cannot be checked, and we never fill them in after the fact.

These are consensus estimates: what analysts expect the business to earn, not where they think the stock trades. Coverage thins and the low to high band widens in the out-years. Context, not advice.

Analysts' price forecasts and grades are not licensed here. This page shows forward consensus estimates only: no near-year analyst count published. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.